1.
Beca J, Majeed H, Chan KK, Hotte SJ, Loblaw A, Hoch JS. Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer. CUAJ [Internet]. 2019Apr.26 [cited 2020Oct.19];13(12):396-403. Available from: https://cuaj.ca/index.php/journal/article/view/5889